C-Reactive Protein-To-Albumin Ratio Is an Independent Poor Prognosis and Improving NCCN-Ipi Score in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Clinical Analysis of 414 Cases

Hematological Oncology - United Kingdom
doi 10.1002/hon.81_2631
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Immunohistochemical Double Hit Score Enhances NCCN-IPI and Is Associated With Detrimental Outcomes in Refractory or Relapsing Patients With Diffuse Large B Cell Lymphoma

British Journal of Haematology
Hematology
2017English

The Derived Neutrophil to Lymphocyte Ratio Is an Independent Prognostic Factor in Patients With Diffuse Large B-Cell Lymphoma

British Journal of Cancer
Cancer ResearchOncology
2013English

Global Hypomethylation Is an Independent Prognostic Factor in Diffuse Large B Cell Lymphoma

American Journal of Hematology
Hematology
2017English

Secondary Cutaneous Diffuse Large B-Cell Lymphoma Has a Higher International Prognostic Index Score and Worse Prognosis Than Diffuse Large B-Cell Lymphoma, Leg Type

Acta Dermato-Venereologica
DermatologyMedicine
2016English

Prognostic Impact of Tumor-Associated Macrophages, Lymphocyte-To-Monocyte and Neutrophil-To-Lymphocyte Ratio in Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Hypogammaglobulinemia and Hypocomplementemia as Strong Prognostic Factors in Newly Diagnosed Diffuse Large B Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Correlation of Pretreatment 18f-FDG Uptake With Clinicopathological Factors and Prognosis in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

Nuclear Medicine Communications
MedicineNuclear MedicineRadiologyImaging
2016English

Red Blood Cell Distribution Width and Platelet Counts Are Independent Prognostic Factors and Improve the Predictive Ability of IPI Score in Diffuse Large B-Cell Lymphoma Patients

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Serum miR-22 as Potential Non-Invasive Predictor of Poor Clinical Outcome in Newly Diagnosed, Uniformly Treated Patients With Diffuse Large B-Cell Lymphoma: An Explorative Pilot Study

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy